A new report highlights the potential risk in concomitant use of the anticoagulant dabigatran, and phenytoin, a P-glycoprotein (P-gp) inducer used to treat seizure disorders.
Rivaroxaban, a non-vitamin K antagonist (VKA) oral anticoagulant, was found to have better persistence and lower discontinuation rates than, the VKA warfarin and the non-VKA, dabigatran.
The study analyzed data from NVAF patients newly initiating treatment with dabigatran, rivaroxaban or apixaban.
Boehringer Ingelheim has announced that Praxbind, a reversal agent for the oral anticoagulant Pradaxa (dabigatran etexilate mesylate), is now available in over 2,200 hospitals across the U.S
Forty-eight percent of atrial fibrillation (AF) patients, who are at the highest risk of stroke, were not prescribed oral anticoagulant (OAC) medication.